SCHEMBL16437441

SCHEMBL16437441

COc1ccc(C(=O)Cn2ncc(Cl)c2C)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 2/20 0.55
▸ PDE4B Q07343 2/20 0.53
▸ CCR1 P32246 1/20 0.52
▸ POLB P06746 2/20 0.49
▸ CTNNB1 P35222 2/20 0.49
▸ WNT3A P56704 2/20 0.49
▸ CYP3A4 P08684 3/20 0.48
▸ CYP2C19 P33261 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ MAPT P10636 4/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ HTT P42858 2/20 0.45
▸ MITF O75030 1/20 0.45
▸ S1PR4 O95977 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ S1PR1 P21453 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16427211 0.85 PDE4D (0.50) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16427380 0.84 PDE4D (0.52) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16437438 0.79 PDE4B (0.52) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16426583 0.77 PDE4B (0.50) PDE4BPOLBCTNNB1WNT3ACYP2C19
SCHEMBL19498643 0.76 CA12 (0.51) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16437437 0.76 PDE4B (0.51) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16437443 0.76 PDE4B (0.48) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL28058790 0.76 PDE4B (0.48) PDE4DPDE4BPOLBCTNNB1WNT3A
SCHEMBL16426964 0.75 PDE4B (0.48) PDE4BPOLBCTNNB1WNT3ACYP2C19
SCHEMBL16427745 0.75 PDE4B (0.50) PDE4DPDE4BPOLBCTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN PDE4D 1210/4885PDE4B 1658/4885CCR1 1205/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN PDE4D 1290/4885PDE4B 1728/4885CCR1 1251/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN PDE4D 1290/4885PDE4B 1728/4885CCR1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback